AbbVie's Skyrizi hangs Novartis' Cosentyx out to dry in head-to-head psoriasis study
Skyrizi, a key drug in AbbVie’s post-Humira future, has added another feather to its cap.
On Tuesday, the IL-23 inhibitor emerged superior in a head-to-head 327-patient trial against Novartis’ dominant Cosentyx in patients with moderate-to-severe plaque psoriasis.
Data showed Skyrizi induced significantly higher rates of skin clearance compared to Cosentyx, meeting the primary goal of superiority with at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52. Overall, 87% of Skyrizi-treated patients hit PASI 90, versus 57% of Cosentyx-treated patients at the one year mark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.